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Abstract
Availability of living organisms to mimic key step of amyloidogenesis of human protein has become an indispensable tool
for our translation approach aiming at filling the deep gap existing between the biophysical and biochemical data obtained
in vitro and the pathological features observed in patients. Human b2-microglobulin (b2-m) causes systemic amyloidosis in
haemodialysed patients. The structure, misfolding propensity, kinetics of fibrillogenesis and cytotoxicity of this protein, in
vitro, have been studied more extensively than for any other globular protein. However, no suitable animal model for b2-m
amyloidosis has been so far reported. We have now established and characterized three new transgenic C. elegans strains
expressing wild type human b2-m and two highly amyloidogenic isoforms: P32G variant and the truncated form DN6
lacking of the 6 N-terminal residues. The expression of human b2-m affects the larval growth of C. elegans and the severity of
the damage correlates with the intrinsic propensity to self-aggregate that has been reported in previous in vitro studies. We
have no evidence of the formation of amyloid deposits in the body-wall muscles of worms. However, we discovered a strict
correlation between the pathological phenotype and the presence of oligomeric species recognized by the A11 antibody.
The strains expressing human b2-m exhibit a locomotory defect quantified with the body bends assay. Here we show that
tetracyclines can correct this abnormality confirming that these compounds are able to protect a living organism from the
proteotoxicity of human b2-m.
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Introduction
Caenorhabditis elegans is an extremely versatile and appropriate
animal model for mimicking and recapitulating in vivo the key
molecular mechanisms underlying the gene-and tissue-specific
protein misfolding and toxicity related to the human pathogenesis
[1]. Despite the evolutionary distance from vertebrates, human
proteins substantially maintain their structure and function when
they are expressed in C. elegans [1]. Many variant proteins
associated to human diseases cause a pathological phenotype in
worms and this cross-species translation greatly facilitates the study
of human diseases in this simple organism. This is particularly true
for ‘‘gain of function diseases’’, including Alzheimer, Parkinson
and Huntington diseases, caused by self-aggregation of specific
peptides [2–4]. Transgenic worms expressing human disease-
relevant proteins and peptides also represented a rapid and highly
informative system for the screening of putative therapeutic
medications at the early stages of drug development with
particular regard to aging-related diseases [5]. Alavez et al. [6]
have recently shown that C. elegans is an excellent biological model
for testing compounds that generically counteract the toxicity of
protein aggregates. The exposure of nematodes to standard
amyloid binding ligands, including thioflavin T and curcumin,
has a beneficial effect on the regulators of protein homeostasis and
significantly improves the worms lifespan [7].
Although C. elegans has been widely employed to investigate a
number of neurodegenerative diseases, its application to the study
of systemic amyloidoses related to human proteins, i.e. lysozyme,
monoclonal light chains, b2-microglobulin (b2-m) and transthyre-
tin (TTR), is limited. A transgenic C. elegans strain expressing wild
type human TTR was generated to investigate its putative
protective role against the amyloid beta (Ab) toxicity rather than
testing the intrinsic amyloidogenic propensity of TTR [8]. Link
and his collaborators showed that the expression of human wild
type or Ala60-mutated TTR protected a C. elegans transgenic strain
from the paralysis induced by Ab3–42 expression but was not
associated, per se, to the formation of amyloid deposits [8] or to any
specific phenotype [9].
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In vivo models of systemic amyloidosis are urgently needed and
this is particularly required for b2-m associated disease where any
attempt to generate an animal model to recapitulate the key
molecular aspects of the pathology have currently failed [10]. b2-m
is the non-covalently bound light chain of the major histocom-
patibility complex class I (MHCI). In patients under chronic
haemodialysis treatment, it dissociates and converts into amyloid
fibrils whose deposition in osteoarticular tissues causes the
pathological condition known as dialysis-related amyloidosis
(DRA) [11]. Extensive work has been carried out to elucidate
the biophysical basis of the propensity of b2-m to make amyloid
fibrils in vitro and identify the specific contribution of a single
amino acid residue to the aggregation kinetics. We have shown
that, under physiological like conditions, b2-m monomers,
spontaneously, form oligomeric species which are on the pathway
of fibril formation [12,13]. A modest acidification, consistent with
the patho-physiologic fluctuations of the pH within the peri-
articular tissue, or a small increase of temperature, that can often
occur during the haemodialysis treatment, strongly enhanced the
protein polymerization [14]. The generation of the first transgenic
C. elegans strains constitutively expressing the wild type b2-m (WT)
and two highly amyloidogenic variants, P32G and the truncated
form at the 6th N-terminal residue (DN6), represent our method to
fill the gap existing between the molecular features analyzed in vitro
and the pathogenic events observed in patients. The P32G variant
[15], which was designed to highlight the role of the native
cisHis31-Pro32 peptide bond in the fibrillogenesis, enhanced the in
vitro amyloidogenic potential of wild type protein. DN6 is a
ubiquitous constituent of b2-m amyloid deposits in patients
affected by DRA and, due to its capacity to act as a seed in the
fibrillogenesis of full length b2-m, it could have a crucial role in
dictating the clinical history of the disease [16].
C. elegans represents a suitable organism to study the tissue
damage associated to b2-m self aggregation since it lacks the
MHCI complex and therefore all the b2-m is expressed in a state
not bound by the MHCI heavy chain. The abundance of not-
bound b2-m mimics what occurs during haemodialysis, where
circulating free b2-m rises 30 to 40 fold [17]. Furthermore, it is
worth noting that both collagen, which is structurally similar to the
human counterpart, and glycosaminoglycans are highly represent-
ed in the basement membrane of the C. elegans muscle system [18]
and are potent promoters of b2-m amyloidogenesis under
physiological like conditions [19]. To recapitulate the aggregation
process occurring in mammals, we expressed the b2-m isoforms in
C. elegans under the control of a body-wall muscle promoter.
Here we show that both the P32G replacement and DN6
truncation remarkably exacerbate the behavioural defects that the
expression of wild type human b2-m causes in transgenic worms.
Mutated and truncated species of b2-m had a greater propensity to
form in vivo soluble oligomeric species than the wild type protein,
thus, indicating that the toxicity of these proteins was strictly
related to their sequence and aggregation propensity.
To determine whether these new transgenic nematodes might
be applied to the screening of compounds that counteract b2-m
amyloidogenesis and amyloid toxicity, we tested their response to
tetracyclines, which have been already reported to inhibit, in vitro,
the b2-m aggregation [20]. These drugs are emerging anti-
amyloidogenic compounds and, their ability to counteract the
aggregation of various amyloidogenic proteins, including TTR
[21], and interact in vitro and in vivo with Ab oligomers has been
already described [22].
Materials and Methods
Construction of C. elegans transgenic strains
Transgenic C. elegans strains were engineered to express human
wild type b2-m and two isoforms, P32G and DN6, under the
control of the body-wall muscle-specific unc-54 promoter/enhanc-
er. Minigenes encoding wild type b2-m and DN6 were assembled
in two steps. Sequence coding for signal peptide containing
compatible cohesive ends (forward sequence: 59-CTAG-
CAAAAATGTCTCGCTCCGTGGCCTTAGCTGTGCTCGC-
GCTACTCTCTCTTTCTGGCCTGGAGGCTGGTAC-39; re-
verse sequence: 59-CAGCCTCCAGGCCAGAAAGAGAGAG-
TAGCGCGAGCACAGCTAAGGCCACGGAGCGAGACATT-
TTTG-39) was inserted between the unique NheI and KpnI sites of
pPD30.38 vector (Addgene) [5]. Subsequently, wild type b2-m and
DN6 sequences (obtained from the plasmids pHN1 and pET11a,
respectively) were amplified by using b2-m cDNA as template and
the oligonucleotide primers 59-GGGGGTACCATCCAGCG-
TACTCCAAAG-39 for the full length, 59-GGGGGTACCATT-
CAGGTTTACTCACGTC-39 for the truncated species and, 39-
CCCGAGCTCTTACATGTCTCGATCCCAC-59 for both spe-
cies. The amplified DNA was inserted between the unique KpnI
and SacI sites of pPD30.38 previously engineered with the signal
peptide. To obtain P32G b2-m plasmid, a site-directed mutagen-
esis of wild type b2-m engineered plasmid pPD30.38 was
performed, using the following primers: 59-CTATGTGTC-
TGGGTTTCATGGATCCGACATTGAAGTTGAC-39 and
59-GTCAACTTCAATGTCGGATCCATGAAACCCAGACAC-
ATAG-39. A pPD30.38 plasmid containing only the signal peptide
was created as control. DNA sequencing was carried out to
confirm that all subcloned plasmids were correct. Transgenes were
introduced into MT309 multivulva C. elegans strain (Caenorhabdi-
tis Genetics Center, CGC, University of Minnesota, USA) by
gonad microinjection of a DNA solution containing 25 ng/ml of
the b2-m construct together with 20 ng/ml of ttx-3::rfp and 30 ng/
ml of plin-15(+) as marker plasmids. Multiple extra-chromosomal
lines were established based on both the fluorescent marker and
the disappearance of the multivulva phenotype. The transgenic
worms maintain the injected DNA as an extra-chromosomal
multiply array of variable mitotic and meiotic stability. The
transmitting lines established for this study have 70–80% meiotic
stability. Thus transgenic worms produce both transgenic and
non-transgenic progeny.
Worms were maintained and propagated at 20uC on solid
Nematode Growth Medium (NGM) seeded with OP50 E. coli
(Caenorhabditis Genetics Center, University of Minnesota, USA)
as food. To prepare age-synchronized animals, nematodes were
transferred to fresh NGM plates after reaching maturity at 3 days
of age and allowed to lay eggs overnight. Isolated hatchlings from
the synchronized eggs (day 1) were cultured on fresh NMG plates
at 20uC.
Genotype characterization
RNA from adult transgenic worms was prepared using the
RNeasy Mini kit (QIAzol Lysis Reagent, Qiagen) and quantified
using the NanoDrop apparatus (ThermoScientific). Total RNA
was reverse transcribed into cDNA with random primers
(Random Hexamers, Applied Biosystems) and the GeneAmp
RNA PCR Core kit (Applied Biosystems). A quantitative real-time
PCR was performed with Mx3000P QPCR System (Stratagene)
using the SYBR Green gene expression assay (Applied Biosystems,
AB). Relative quantification of mRNA level was determined using
two endogenous standard gene controls, i.e. peripheral myelin
gene PMP-22/GAS-3 and cell division cycle 42 (cdc-42, GTP
C. elegans Models for b2-m Amyloidosis
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binding protein) according to Hoogewijs [23] and, data analysis
was performed with MxPro QPCR Software (Stratagene). All
measurements were determined in triplicate. Data points collected
correspond to the number of PCR cycles (Ct value) required for
the fluorescent signal to cross the detection threshold of the
thermal cycler. Ct values were normalized to correct for minor
differences in cDNA concentrations by subtracting the average of
the Ct values of the reactions in triplicate of each transgenic strain
from the geometric mean of Ct values of cdc-42 reactions, and
analyzed using the comparative 22DDCt method [24].
b2-m expression
Transgenic worms were collected with M9 buffer, transferred to
tubes, centrifuged and washed twice to remove bacteria. The pellet
containing worms was resuspended in lysis buffer (25 mM Tris,
pH 7.5, containing 5 mM NaCl, 5 mM EDTA, 1 mM dithio-
threitol, DTT, and protease inhibitor mixture) and homogenized
by sonication. For dot-blot analysis, equal amounts of proteins
from homogenized samples (5 mg) were spotted onto nitrocellulose
membranes (Millipore), blocked with 5 mM phosphate buffered
solution, pH7.4 containing 0.1% Tween 20 (PBS-T) and
incubated overnight with a rabbit polyclonal anti-human b2-m
antibody (1:1000 dilution, Dako) or a rabbit polyclonal antibody
recognizing high molecular weight oligomers (A11, 1:1000
dilution, Biosource, USA). Anti-rabbit IgG peroxidase conjugate
(1:10000 dilution, Sigma) was used as secondary antibody.
Immunoreactive bands were detected by ECL chemiolumines-
cence (Millipore) and quantified with Quantity One Image
Software (Biorad). Data are expressed as density/mg of protein.
The b2-m species in transgenic populations were identified by
western blotting [22]. Equal amounts of protein lysates were
filtered using a 30K cut off filter device (Millipore) and, flow
through samples were loaded onto gradient 8–18% Excel SDS gel
(GE Healthcare) for electrophoresis performed under reducing
conditions. Proteins were transferred to Immobilon P membranes
and blot was developed with a rabbit polyclonal anti human b2-m
antibody (1:1000 dilution, Dako) and anti-rabbit IgG peroxidase
conjugate (1:10000 dilution, Sigma) as primary and secondary
antibody respectively. Chemioluminescent substrate was used as
above.
Immunofluorescence
Fluorescence microscopy analysis was carried out on whole
worms [25,26]. Briefly, egg-synchronized L4/young adult worms
were collected, rinsed and fixed in 2% p-formaldehyde solution.
Fixed worms were subjected to thermal shock and washed twice in
100 mM Tris-HCl solution pH7.4, containing 1% (v/v) Triton X-
100 and 1 mM EDTA. Samples were reduced with 2 hours
incubation, 37uC, using the same buffer containing 1% b-
mercaptoethanol followed by further 15 min incubation, in
25 mM H3BO3 solution, pH9.2, containing 10 mM DTT, at
room temperature. Subsequent steps included: incubation in
25 mM H3BO3, pH 9.2, containing 1% H2O2, room temperature
for 15 min; extensive washing in 5 mM PBS pH7.4, containing
1% bovine serum albumin, 0.5% Triton X-100, 0.05% sodium
azide and, 1 mM EDTA; overnight incubation with the rabbit
polyclonal anti- human b2-m antibody (1:100 dilution, Dako), 4uC;
extensive washing as above; overnight incubation with an IgG
Alexa Fluor 546 goat anti-rabbit antibody (1:200 dilution,
Invitrogen), 4uC. Samples were then mounted on slides for
microscopy and observed with an inverted fluorescent microscope
(IX-71 Olympus) equipped with a CDD camera (F- VEWII) and
images captured.
Larval growth
One hundred synchronized eggs were plated on fresh NMG
plates seeded with OP50, left at 20uC and the number of worms at
L1/L2, L2/L3 and L4/adult larval stage were scored after 13, 22
and 40 hours, respectively.
Life-span
Gravid worms were allowed to lay eggs for 3–4 hours at 20uC,
to produce an age-synchronized population. Once the worms
reached their reproductive maturity, they were transferred daily
until the cessation of egg lying to avoid overlapping generations.
Nematodes were transferred every day and their viability
monitored until all the worms were scored as dead when they
failed to display touch-provoked movement.
Body Bends assay
Body Bends assays were performed at room temperature using a
stereomicroscope (M165 FC Leica) equipped with a digital camera
(Leica DFC425C and SW Kit). L3–L4 worms were picked and
transferred into a 96-well microtiter plate containing 100 ml of
ddH2O. The number of left-right movements in a minute was
recorded.
To determine the effect of tetracycline in preventing the
locomotory defect caused by b2-m expression, egg-synchronized
transgenic worms (100worms/plate) were placed into fresh NMG
plates, 20uC and, seeded with tetracycline-resistant E. coli [22].
After thirty-six hours, at their L3/L4 larval stage, worms were fed
with 50–100 mM tetracycline hydrochloride or doxycycline
(100 ml/plate) and body bends in liquid were scored after
24 hours. Tetracycline hydrochloride and doxycycline were from
Fluka (Switzerland) and were freshly dissolved in water before use.
Pharyngeal pumping assay
Individual L3/L4 transgenic worms were placed into NMG
plates seeded with E. coli and the pumping behaviour was scored
by counting the number of times the terminal bulb of the pharynx
contracted over a 1-minute interval.
Superoxide production
Superoxide anions, in synchronized L3/L4 worms, were
estimated using the colorimetric nitro blue tetrazolium (NBT)
assay [27]. Superoxide anions were measured in 100 ml sample
volume added with 1.5 ml of 50 nM phorbol myristate acetate,
50 ml of 1.8 mM NBT (Sigma-Aldrich, St Louis, MO, USA) and,
incubated at 37uC for 30 min. Absorbance was read at 560 nm
against blank samples without worm homogenate (Infinite M200
multifunctional micro-plate reader, Tecan, Austria). Superoxide
production was expressed as percentage of NBT (absorbance/mg
of protein) compared to untreated control worms. The protein
content was determined using Bio-Rad Protein assay (Bio-Rad
Laboratories GmbH, Munchen, Germany).
Fluorescent staining of amyloid
Age-synchronized transgenic worms were fixed in 4% parafor-
maldehyde/PBS pH7.4 for 24 hours at 4uC. Nematodes were
stained with 1 mM 1,4-bis(3-carboxy-hydroxy-phenylethenyl)-
benzene (X-34) in 10 mM Tris-HCl, pH 8.0 for 4 hours at room
temperature [8], destained, mounted on slides for microscopy and
observed with inverted fluorescent microscope (IX-71 Olympus);
images were acquired with a CDD camera.
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Statistical analysis
Data were analyzed using independent Student’s t-test and
One-way ANOVA test with GraphPad Prism 4.0 software (CA,
USA). A p value,0.05 was considered statistically significant.
Results
We generated three new transgenic C. elegans strains expressing
human wild type b2-m and two highly amyloidogenic variants and
used these novel animal models to elucidate the putative
correlation between the aggregation of b2-m and its in vivo
proteotoxicity.
Reverse transcription of total RNA, followed by PCR and
sequence analysis of the resulting cDNA, confirmed the exact
genotype of the three transgenic strains. PCR products, from all
the nematode strains, show the expected size of 360 bp (Figure 1A).
The relative quantity of human b2-m mRNA, normalized to worm
cdc-42 content, was significantly higher in both P32G and DN6
expressing worms than in WT strain (p,0.01, one-way ANOVA)
(Figure 1B).
To correlate the mRNA level with the amount of b2-m
expressed in the different transgenic strains, worm lysates were
analyzed by dot blotting using polyclonal anti-human b2-m
antibody. Although a faint unspecific band was detected in worms
transfected with the empty vector, an increase in b2-m related
signal was observed in WT, P32G and DN6 expressing nematodes
as shown in Figure 2A. Quantification of the immunoreactive dots
indicated that both WT and P32G transgenic strains expressed
comparable b2-m levels (0.3260.04 and 0.3460.06 density/mg
protein for WT and P32G, respectively) whereas a lower, but not
statistically significant, protein content was detected in DN6
animals (0.1960.05 density/mg protein) (Figure 2B). SDS-PAGE
and Western blot immunostained with polyclonal anti human b2-
m antibody confirms the relative abundance of the three isoforms
(Figure 2C).
The ratio between the relative amount of mRNA and dot-blot
immunoreactive b2-m signals of the three variants is 26, 67 and
125 for WT, P32G and DN6, respectively. These findings suggest
that the higher transcription level of P32G and DN6 cDNA
compared to WT does not result in different b2-m protein
concentration among the three strains. The dissociation between
the mRNA transcription and the protein level is consistent with a
putative role of the quality control system in removing the
misfolded conformers that are particularly abundant in the case of
the two highly amyloidogenic species. The western blot in
Figure 2C shows the presence of a monomeric b2-m band in the
lysates and a smear of aggregated protein that, despite extensive
centrifugation and filtration is particularly evident in P32G and
DN6 samples. Such a feature is also consistent with the well-
established propensity of these b2-m isoforms to misfold and self-
aggregate [15,16].
The ability of the three b2-m isoforms to form oligomeric
structures in vivo was then explored by performing dot-blot analysis
on lysates of worms using the A11 antibody that specifically
recognizes the amyloid oligomers. The expression of wild type
protein was accompanied by a small A11-positive signal, which
became stronger in transgenic worms expressing the two variants
(Figure 2D). The quantification of the A11-immunoreactivity
indicated that the oligomerization significantly increased 4.8 and
4.3 fold in P32G and DN6 mutants, respectively, compared to WT
(Figure 2E, p,0.01 vs. WT, one-way ANOVA).
Immunofluorescence studies were carried out to visualize the
b2-m in transgenic C. elegans strains. A b2-m-positive signal was
observed in the vulva muscles and anal sphincter muscle in the tail
regions: it begun at larval stages of WT, P32G and DN6 animals
(data not shown) and became maximal at day 1-adult age
(Figure 3). No signal was detected in worms that were transfected
either with the empty vector or alternatively in the head (data not
shown). The constitutive expression of the wild type or variant b2-
m did not lead to the formation of amyloid fibrils, since no X-34
reactive deposits were detected in the vulva and tail muscles of 2
days-old transgenic worms (Figure S1).
We also investigated whether the expression of the different
isoforms of human b2-m resulted in specific toxic behavioural
phenotypes. First of all, the effect on the larval growth was
considered. Larval growth in C. elegans is known to be exponential;
Figure 1. Genotype of C. elegans transgenic strains. (A) PCR genotyping of adult transgenic worms transfected with the empty vector (vector)
or vectors for expression of wild type b2-m (WT), P32G or 7–99 truncated form (DN6). The expected size of PCR products (about 360 bp) was
observed. (B) Human b2-m mRNA expression in different transgenic strains was normalized to worm cell division cycle 42 (cdc-42, GTP binding
protein) as endogenous reference. Data are expressed as mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0052314.g001
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therefore the growth rate is constant within larval phases and,
reached a plateau in late adulthood [28]. After synchronization,
the numbers of worms were scored after 24, 48 and 72 hours that
correspond to the L1/L2, L2/L3 and L4/adult larval stages,
respectively. WT nematodes exhibited a constant number of
worms and a constant growth rate similarly to that observed in
animals transfected with the empty vector (Figure 4A). In P32G
and DN6 transgenic C. elegans strains, the percentage of worms
reaching the L1/L2 stage was significantly reduced than in WT
(83.3% for WT and 27.6% and 37.8% for P32G and DN6,
respectively, p,0.01 vs. WT, one-way ANOVA). The irregular
growth rate compared to WT was also observed at the L2/L3
larval stage (81.4% for WT and 20.0% and 18.7% P32G and
DN6, respectively, p,0.01 vs. WT, one-way ANOVA, Figure 4A).
This resulted in a significant reduction in the percentage of worms
reaching the adulthood, being the 88.6% for WT nematodes and
13.8% and 22.9% for P32G and DN6 transgenic animals,
respectively (p,0.01vs. WT, One-way ANOVA) and indicates
that the expression of the mutated or truncated isoforms of the
protein affected the nematodes growth and development.
The phenotypic abnormality well correlated with the aggrega-
tion pathway of b2-m. In particular, a correlation coefficient of
R= 0.979 was determined when the percentage of transgenic
worms reaching the adulthood, 72 hours after synchronization,
was plotted with the amount of A11-positive oligomeric assemblies
detected by dot blotting (Figure 4B).
To determine whether b2-m affected the health of nematodes
and their lifespan, the overall nematodes survival was evaluated.
The expression of wild type b2-m significantly decreased the
median lifespan of transgenic worms compared to nematodes
injected with the empty vector (Figure 4C, median survival
respectively: 13 days and 10 days for Vector and WT, p,0.05,
Wilcoxon test). The insertion of both the P32G mutated gene and
deleted DN6 sequence similarly shortened the survival of worms
by 38% compared to the empty vector (median of survival: 8 days
for both P32G and DN6, p,0.001 vs. Vector, Wilcoxon test) and
by 20% compared to WT (p,0.01, Wilcoxon test). Thus,
nematodes expressing the mutated or truncated gene had a
shorter lifespan, indicating that, in vivo, P32G and DN6 show a
greater proteotoxicity than WT b2-m.
The presence of misfolded proteins in body wall muscle cells can
induce dysfunctions in the coordination and motility of C. elegans
[6].
Figure 2. Human b2-m protein expression. (A) Representative dot blot of b2-m (polyclonal anti-human b2-m antibody) in transgenic worms and
(B) quantification of b2-m immunoreactive bands. Data are mean values of density of immunoreactive bands/mg of protein 6 SE of three
independent experiments (N = 6). (C) Representative western blot of b2-m in control worms (vector), wild type b2-m expressing worms (WT), and in
nematodes expressing P32G (P32G) or DN6 b2-m isoform (DN6). Day 1 adult worms were collected, processed as described in Methods section, and
equal amounts of proteins (40 mg) were loaded on each lane and immunoblotted with polyclonal anti-human b2-m antibody (Dako). (D)
Representative dot blot developed by antibody recognizing oligomers (A11) in transgenic worms and (E) quantification of A11-immunoreactive
bands. Data are expressed as mean of density of A11 immunoreactive bands/mg of protein 6 SE of three independent experiments (N = 9); *p,0.01
vs WT, according to one-way ANOVA.
doi:10.1371/journal.pone.0052314.g002
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We investigated whether the presence of b2-m in vulva muscles
affected the locomotion. It is well known that, in the vulva,
hermaphrodite-specific motor neurons make extensive neuromus-
cular junctions with the vulva muscles affecting the coordination of
egg-laying and locomotion (http://www.wormbook.org/chapters/
www_egglaying/egglaying.html). The locomotion activity in liquid
of b2-m expressing worms was then evaluated by quantifying their
body bends. Worms transfected with the empty vector had a
motility similar to ancestral N2 animals (vector, 158.6623 body
bends/min, N2, 170.3615, N=70) indicating that insertion of the
transgene without b2-m construct did not affect locomotion. A
significant reduction of the body bends, compared to the empty
vector, was observed in both WT animals and in worms expressing
the two b2-m variants. In particular, we observed a significant
decrease of the number of body bends per minute by 15% and
18% in WT and DN6 expressing strains, respectively. Nematodes
expressing P32G mutated gene had a worse motility than WT and
DN6 animals (p,0.01, one-way ANOVA) with a 32% reduction
in body bends compared to worms transfected with the empty
vector (Figure 4D).
Oxidative stress is known to occur in transgenic C. elegans strains
expressing amyloidogenic proteins [29,30]. We determined
superoxide production in b2-m expressing worms at L3/L4 larval
stage. Superoxide levels rose significantly in all b2-m expressing
transgenic strains compared to worms transfected with the empty
vector (Figure 4E). In addition, nematodes expressing the two b2-
m variants, DN6 and P32G, generated more oxygen free radicals
compared to WT indicating that b2-m isoforms affect the
superoxide production (Figure 4E).
To determine whether the new transgenic nematodes can be
used for testing in vivo the pharmacological effect of compounds
inhibiting amyloidogenesis and amyloid toxicity [22], we investi-
gated the ability of tetracyclines to counteract b2-m proteotoxicity
in vivo. Worms were fed with either vehicle or 50–100 mM
tetracycline hydrochloride for 24 hours and body bends were
scored. As shown in Figure 5, 50 mM tetracycline completely
abolished the body bends reduction caused by WT b2-m
expression in worms, whereas it resulted ineffective in P32G and
DN6 nematodes. A higher dose of 100 mM tetracycline was
required to recover the locomotory defect in transgenic C. elegans
strains expressing the two variants. The number of body bends of
worms transfected with the empty vector was not affected by
tetracycline administration (data not shown). Similar effects were
observed after feeding worms with doxycycline, another tetracy-
cline-derived compound that was shown to be effective in vitro
against the b2-m aggregation and cytotoxicity (Figure 5) [20].
Discussion
We report the first model of transgenic C. elegans expressing and
directing human b2-m in the muscular system. The comparative
analysis of the phenotype of strains expressing the wild type
protein and two highly amyloidogenic isoforms of b2-m suggests
that protein misfolding and aggregation propensity, that were
previously observed in vitro [15,16], are confirmed in vivo using this
complex living organism.
Although we have not found genuine amyloid fibrils in the
worms, the strains expressing P32G and DN6 generate a higher
amount of oligomeric species that are generally considered the
toxic species of amyloid aggregates. The ratio between the amount
of b2-m expressed in each C. elegans transgenic strain and the level
of mRNA (protein/mRNA) suggests that, when the mutated and
truncated forms of b2-m are produced, the worms activate a
degradative response toward the more amyloidogenic species. This
is particularly informative for the truncated form of b2-m (DN6)
that is ubiquitously present in all the amyloid deposits of patients
affected by DRA [31] where DN6 is considered a strong promoter
of amyloidogenesis of wild type b2-m [32]. Its susceptibility to
proteolytic degradation is well documented by studies of limited
proteolysis [33] and is consistent with the evidence that, in DRA
patients, the DN6 is confined to the amyloid fibrils where is
Figure 3. Localization of b2-m in transgenic C. elegans strains. Overlay of bright field and immunofluorescence images of head, vulva and tail
of transgenic C. elegans strains. All animals depicted are 2 days adult worms. A specific b2-m related signal (red, using a polyclonal anti human b2-m
antibody) was observed at the vulva muscles and anal sphincter muscle in the tail (red arrows) whereas no signal was observed in the head muscles.
Scale bar, 50 mm.
doi:10.1371/journal.pone.0052314.g003
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protected from proteolytic degradation, but it is undetectable in
circulating blood [31]. Even thought the amount of DN6 escaping
the quality control machinery is probably lower than that of wild
type b2-m, the kinetics of DN6 self-aggregation in C. elegans is so
fast and efficient that a population of cytotoxic oligomeric b2-m is
nonetheless formed. Data regarding the P32G variant can be
similarly interpreted, although we cannot assume any clinical-
pathologic correlation in humans because it only represents a
protein model.
It is worth of note that the expression of wild type full-length b2-
m, per se, affects the physiology of the worm, but the expression of
the two more amyloidogenic species highly enhanced the damage
to the biological cycle of the worms. The harm caused by b2-m
might depend on the aggregated species, as demonstrated by the
statistically significant inverse correlation that we observed
between the concentration of oligomers and larval growth
(Figure 4B). A crucial role on larval development is played by
mitochondrial efficiency [34], and mitochondria represent sensi-
tive target of the cytotoxic amyloid aggregates generated by several
amyloidogenic peptides [35] and proteins [36]. The increased
concentration of the reactive oxygen species, produced in all the C.
elegans strains and, particularly in those expressing the P32G and
Figure 4. Behavioural phenotypes of transgenic C. elegans strains. (A) Larval growth of control worms (Vector), wild type b2-m expressing
worms (WT) and nematodes expressing P32G or 7–99 truncated form of b2-m (DN6). One hundred synchronized eggs were placed into fresh NMG
plates seeded with OP50 as food, and the number of L1/L2, L2/L3 and L4/adult worms were scored after 24, 48 and 72 hours, respectively. Data are
expressed as percentage of total worms in the plate at each time point and are given as mean of three independent experiments (N= 300). (B)
Correlation between oligomers of b2-m and reduction in growth rate of transgenic C. elegans strains. Percentage of adult worms of each transgenic
strain, scored 72 after egg synchronization, was correlated to the the amount of A11-positive oligomeric assemblies detected by dot blotting. Data of
both graphic axes represent mean of three independent experiments. (C) Kaplan-Meier survival curves of transgenic hermaphrodite adult
nematodes. Animals were placed in plates seeded with OP50 starting from L4, cultured at 20uC and transferred to fresh plates for each consecutive
other days. Survival rate was scored every day and expressed as percent of survival. Plots are representative of three independent experiments
(N = 30). (D) Body bends in liquid of transgenic worms. At least three independent assays were performed (N= 100 animals for each group). Data are
given as mean of number of body bends/min 6 SE, *p,0.05 and **p,0.01 vs. the vector, uup,0.01 vs. WT, according to one-way ANOVA. (E)
Superoxide anions production in control worms (Vector), wild type b2-m expressing worms (WT) and in nematodes expressing P32G or 7–99
truncated form of b2-m (DN6). Age-synchronized worms were collected in PBS containing 1.6 ml of 1% Tween 20 and colorimetric NBT assay was
carried out as described in Materials and Methods. Results show the fold increase in superoxide production calculated as NBT absorbance/mg of
proteins (% NBT) compared to Vector; *p,0.05 vs. vehicle and u p,0.05 vs. WT, according to one-way ANOVA. Error bars indicate SD.
doi:10.1371/journal.pone.0052314.g004
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DN6 b2-m (Figure 4E), is perfectly consistent with the involvement
of the mitochondrial function in the mechanism of toxicity.
In addition to abnormalities of the biological cycle, worms
expressing b2-m, display significant defects in locomotory function
documented through the analysis of the frequency of body bends.
This abnormality is reported in other C. elegans strains that express
other fibrillogenic polypeptides including Ab protein, synuclein
and huntingtin [2,37] and, therefore, the damage observed in the
b2-m transgenes might be common to other amyloidogenic
proteins in their oligomeric state. Deposition of protein aggregates
in the vulva and the tail, as it occurs in our transgenes, can severely
affect the locomotion of worms [38], however we cannot exclude
that soluble b2-m oligomers could cause per se a systemic
cytotoxicity thus damaging the efficiency of muscles not directly
targeted by deposition of protein aggregates.
We are aware that this model is susceptible to several
improvements and variations such as the expression of b2-m in
other organs than muscles, but currently it represents the only
available system of expression of human b2-m in a living organism.
It can also be used for studying other isoforms of b2-m, including
the first amyloidogenic variant of b2-m which causes a systemic
amyloidosis unrelated to the haemodialytic procedure [39].
Nevertheless animal models of b2-m related amyloidosis are
essential to discover and validate new effective drugs. The capacity
of tetracyclines to abrogate the locomotory abnormalities caused
by b2-m expression is remarkable and, indicate that the C. elegans
strains can be considered for testing, in living complex organisms,
the pre-clinical efficacy of molecules, whose capacity of inhibiting
fibrillogenesis and cytotoxicity of b2-m, have been tested only with
isolated proteins and cell cultures [20,40].
Supporting Information
Figure S1 X-34 staining of whole transgenic worms.
Representative images of X-34 staining of whole-mount and fixed
sections of WT and P32G transgenic worms. Animals depicted are
1–2 day adult worms. X-34 staining was visualized at short
wavelength excitation. Red arrows pointed at vulva muscles and
anal sphincter muscle in the tail where a specific b2-m related
signal was observed with immunofluorescence studies (see
Figure 3). The X-34 signal observed was not due to amyloid
deposition but to intestine related non-specific background. Scale
bar, 20 mm.
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